schliessen

Filtern

 

Bibliotheken

Risk assessment for recurrent venous thrombosis

Summary Venous thrombosis is a common disease that frequently recurs. Recurrence can be prevented by anticoagulants, albeit at the cost of bleeding. Thus, assessment of the risk of recurrence is important to balance the risks and benefits of anticoagulation treatment. Many clinical and laboratory ri... Full description

Journal Title: The Lancet (British edition) 2010, Vol.376 (9757), p.2032-2039
Main Author: Kyrle, Paul Alexander, Dr
Other Authors: Rosendaal, Frits R, Prof , Eichinger, Sabine, MD
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: Kidlington: Elsevier Ltd
ID: ISSN: 0140-6736
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_856782505
title: Risk assessment for recurrent venous thrombosis
format: Article
creator:
  • Kyrle, Paul Alexander, Dr
  • Rosendaal, Frits R, Prof
  • Eichinger, Sabine, MD
subjects:
  • Abridged Index Medicus
  • Anticoagulants
  • Anticoagulants (Medicine)
  • Biological and medical sciences
  • Biomarkers - blood
  • Blood and lymphatic vessels
  • Blood clot
  • Blood clots
  • Blood Coagulation
  • Cardiology. Vascular system
  • Diagnosis
  • Diseases
  • Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
  • Dosage and administration
  • Drug therapy
  • Factor V - genetics
  • General aspects
  • Health risk assessment
  • Humans
  • Incidence
  • Internal Medicine
  • Kaplan-Meier Estimate
  • Medical sciences
  • Methods
  • Mortality
  • Mutation
  • Prognosis
  • Prothrombin - genetics
  • Pulmonary Embolism - etiology
  • Pulmonary Embolism - prevention & control
  • Relapse
  • Risk Assessment
  • Risk Factors
  • Secondary Prevention
  • Thrombosis
  • Usage
  • Venous Thrombosis - complications
  • Venous Thrombosis - diagnosis
  • Venous Thrombosis - epidemiology
  • Venous Thrombosis - etiology
  • Venous Thrombosis - prevention & control
ispartof: The Lancet (British edition), 2010, Vol.376 (9757), p.2032-2039
description: Summary Venous thrombosis is a common disease that frequently recurs. Recurrence can be prevented by anticoagulants, albeit at the cost of bleeding. Thus, assessment of the risk of recurrence is important to balance the risks and benefits of anticoagulation treatment. Many clinical and laboratory risk factors for recurrent venous thrombosis have been established. Nevertheless, prediction of recurrence in an individual patient remains a challenge. Detection of some laboratory markers is associated with only a moderate risk of recurrence, and the relevance of others is not known. Many patients have several risk factors and the effect of combined defects is obscure. Routine screening for these laboratory markers should therefore be abandoned. Risk assessment can be improved by measurement of global markers that encompass the effects of clotting and fibrinolytic disorders. Analysis of preliminary data suggests that risk assessment can also be refined through integration of prothrombotic coagulation changes and clinical risk factors.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6843834
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_856782505
sourceformatXML
sourcesystemPC
galeidA244293467
sourcerecordidA244293467
originalsourceidFETCH-LOGICAL-1659t-eac256b74063df596bd61d0f263db94430ac1c561bc491cb88a51dfa85c0e37f3
addsrcrecordideNqFkm1rFDEUhYModrv6E5RFERWcNu8zg1ApxTcoCL6A30Imk2zTziQ1d6bQf29md13tIizzYUh4zuHce4LQE4KPCCby-BsmHBeyZPIVwa8lriUt6D00I7zkheDlz_totkUO0CHAJcaYSyweogNKCCOY1TN0_NXD1UIDWIDehmHhYloka8aUptONDXGExXCRYt9E8PAIPXC6A_t485-jHx_efz_7VJx_-fj57PS8IFLUQ2G1oUI2JceStU7UsmklabGj-djUnDOsDTFCksbwmpimqrQgrdOVMNiy0rE5ern2vU7x12hhUL0HY7tOB5sTqUrIsqICi_0kqSTnuJSZfLZDXsYxhTxGhsockpVVhp6voaXurPLBxSFpM1mqU8o5rRnPG52jo_9Q-Wtt700M1vl8f0fw5h9BM4IPeeM-gF9eDLDUI8BdXKxxkyJAsk5dJ9_rdKsIVlP_atW_msqdrlb9K5p1Tzcjjk1v263qT-EZeLEBNBjduaSD8fCXY5LhikxbfbsTwPhBDz6GPKjv9sZ4t1bb_ERuvE0KjLfB2NbntzWoNvq9Dic7DqbzwefIV_bWwrY4ooAqvDaZPAheOVD2G6i1794
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid817596378
display
typearticle
titleRisk assessment for recurrent venous thrombosis
sourceAlma/SFX Local Collection
creatorKyrle, Paul Alexander, Dr ; Rosendaal, Frits R, Prof ; Eichinger, Sabine, MD
creatorcontribKyrle, Paul Alexander, Dr ; Rosendaal, Frits R, Prof ; Eichinger, Sabine, MD
descriptionSummary Venous thrombosis is a common disease that frequently recurs. Recurrence can be prevented by anticoagulants, albeit at the cost of bleeding. Thus, assessment of the risk of recurrence is important to balance the risks and benefits of anticoagulation treatment. Many clinical and laboratory risk factors for recurrent venous thrombosis have been established. Nevertheless, prediction of recurrence in an individual patient remains a challenge. Detection of some laboratory markers is associated with only a moderate risk of recurrence, and the relevance of others is not known. Many patients have several risk factors and the effect of combined defects is obscure. Routine screening for these laboratory markers should therefore be abandoned. Risk assessment can be improved by measurement of global markers that encompass the effects of clotting and fibrinolytic disorders. Analysis of preliminary data suggests that risk assessment can also be refined through integration of prothrombotic coagulation changes and clinical risk factors.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(10)60962-2
3PMID: 21131039
4CODEN: LANCAO
languageeng
publisherKidlington: Elsevier Ltd
subjectAbridged Index Medicus ; Anticoagulants ; Anticoagulants (Medicine) ; Biological and medical sciences ; Biomarkers - blood ; Blood and lymphatic vessels ; Blood clot ; Blood clots ; Blood Coagulation ; Cardiology. Vascular system ; Diagnosis ; Diseases ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Dosage and administration ; Drug therapy ; Factor V - genetics ; General aspects ; Health risk assessment ; Humans ; Incidence ; Internal Medicine ; Kaplan-Meier Estimate ; Medical sciences ; Methods ; Mortality ; Mutation ; Prognosis ; Prothrombin - genetics ; Pulmonary Embolism - etiology ; Pulmonary Embolism - prevention & control ; Relapse ; Risk Assessment ; Risk Factors ; Secondary Prevention ; Thrombosis ; Usage ; Venous Thrombosis - complications ; Venous Thrombosis - diagnosis ; Venous Thrombosis - epidemiology ; Venous Thrombosis - etiology ; Venous Thrombosis - prevention & control
ispartofThe Lancet (British edition), 2010, Vol.376 (9757), p.2032-2039
rights
0Elsevier Ltd
12010 Elsevier Ltd
22015 INIST-CNRS
3Copyright © 2010 Elsevier Ltd. All rights reserved.
4COPYRIGHT 2010 Elsevier B.V.
5Copyright Elsevier Limited Dec 11-Dec 17, 2010
lds50peer_reviewed
citedbyFETCH-LOGICAL-1659t-eac256b74063df596bd61d0f263db94430ac1c561bc491cb88a51dfa85c0e37f3
citesFETCH-LOGICAL-1659t-eac256b74063df596bd61d0f263db94430ac1c561bc491cb88a51dfa85c0e37f3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23630815$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21131039$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Kyrle, Paul Alexander, Dr
1Rosendaal, Frits R, Prof
2Eichinger, Sabine, MD
title
0Risk assessment for recurrent venous thrombosis
1The Lancet (British edition)
addtitleLancet
descriptionSummary Venous thrombosis is a common disease that frequently recurs. Recurrence can be prevented by anticoagulants, albeit at the cost of bleeding. Thus, assessment of the risk of recurrence is important to balance the risks and benefits of anticoagulation treatment. Many clinical and laboratory risk factors for recurrent venous thrombosis have been established. Nevertheless, prediction of recurrence in an individual patient remains a challenge. Detection of some laboratory markers is associated with only a moderate risk of recurrence, and the relevance of others is not known. Many patients have several risk factors and the effect of combined defects is obscure. Routine screening for these laboratory markers should therefore be abandoned. Risk assessment can be improved by measurement of global markers that encompass the effects of clotting and fibrinolytic disorders. Analysis of preliminary data suggests that risk assessment can also be refined through integration of prothrombotic coagulation changes and clinical risk factors.
subject
0Abridged Index Medicus
1Anticoagulants
2Anticoagulants (Medicine)
3Biological and medical sciences
4Biomarkers - blood
5Blood and lymphatic vessels
6Blood clot
7Blood clots
8Blood Coagulation
9Cardiology. Vascular system
10Diagnosis
11Diseases
12Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
13Dosage and administration
14Drug therapy
15Factor V - genetics
16General aspects
17Health risk assessment
18Humans
19Incidence
20Internal Medicine
21Kaplan-Meier Estimate
22Medical sciences
23Methods
24Mortality
25Mutation
26Prognosis
27Prothrombin - genetics
28Pulmonary Embolism - etiology
29Pulmonary Embolism - prevention & control
30Relapse
31Risk Assessment
32Risk Factors
33Secondary Prevention
34Thrombosis
35Usage
36Venous Thrombosis - complications
37Venous Thrombosis - diagnosis
38Venous Thrombosis - epidemiology
39Venous Thrombosis - etiology
40Venous Thrombosis - prevention & control
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2010
recordtypearticle
recordideNqFkm1rFDEUhYModrv6E5RFERWcNu8zg1ApxTcoCL6A30Imk2zTziQ1d6bQf29md13tIizzYUh4zuHce4LQE4KPCCby-BsmHBeyZPIVwa8lriUt6D00I7zkheDlz_totkUO0CHAJcaYSyweogNKCCOY1TN0_NXD1UIDWIDehmHhYloka8aUptONDXGExXCRYt9E8PAIPXC6A_t485-jHx_efz_7VJx_-fj57PS8IFLUQ2G1oUI2JceStU7UsmklabGj-djUnDOsDTFCksbwmpimqrQgrdOVMNiy0rE5ern2vU7x12hhUL0HY7tOB5sTqUrIsqICi_0kqSTnuJSZfLZDXsYxhTxGhsockpVVhp6voaXurPLBxSFpM1mqU8o5rRnPG52jo_9Q-Wtt700M1vl8f0fw5h9BM4IPeeM-gF9eDLDUI8BdXKxxkyJAsk5dJ9_rdKsIVlP_atW_msqdrlb9K5p1Tzcjjk1v263qT-EZeLEBNBjduaSD8fCXY5LhikxbfbsTwPhBDz6GPKjv9sZ4t1bb_ERuvE0KjLfB2NbntzWoNvq9Dic7DqbzwefIV_bWwrY4ooAqvDaZPAheOVD2G6i1794
startdate2010
enddate2010
creator
0Kyrle, Paul Alexander, Dr
1Rosendaal, Frits R, Prof
2Eichinger, Sabine, MD
general
0Elsevier Ltd
1Elsevier
2Elsevier B.V
3Elsevier Limited
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
100TT
110TZ
120U~
133V.
147QL
157QP
167RV
177TK
187U7
197U9
207X7
217XB
2288A
2388C
2488E
2588G
2688I
278AF
288AO
298C1
308C2
318FE
328FH
338FI
348FJ
358FK
368G5
37ABUWG
38AN0
39ASE
40AZQEC
41BBNVY
42BEC
43BENPR
44BHPHI
45C1K
46DWQXO
47FPQ
48FYUFA
49GHDGH
50GNUQQ
51GUQSH
52H94
53HCIFZ
54K6X
55K9-
56K9.
57KB0
58KB~
59LK8
60M0R
61M0S
62M0T
63M1P
64M2M
65M2O
66M2P
67M7N
68M7P
69MBDVC
70NAPCQ
71PQEST
72PQQKQ
73PQUKI
74Q9U
75S0X
767X8
777QH
787U1
797U2
807UA
sort
creationdate2010
titleRisk assessment for recurrent venous thrombosis
authorKyrle, Paul Alexander, Dr ; Rosendaal, Frits R, Prof ; Eichinger, Sabine, MD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1659t-eac256b74063df596bd61d0f263db94430ac1c561bc491cb88a51dfa85c0e37f3
rsrctypearticles
prefilterarticles
languageeng
creationdate2010
topic
0Abridged Index Medicus
1Anticoagulants
2Anticoagulants (Medicine)
3Biological and medical sciences
4Biomarkers - blood
5Blood and lymphatic vessels
6Blood clot
7Blood clots
8Blood Coagulation
9Cardiology. Vascular system
10Diagnosis
11Diseases
12Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
13Dosage and administration
14Drug therapy
15Factor V - genetics
16General aspects
17Health risk assessment
18Humans
19Incidence
20Internal Medicine
21Kaplan-Meier Estimate
22Medical sciences
23Methods
24Mortality
25Mutation
26Prognosis
27Prothrombin - genetics
28Pulmonary Embolism - etiology
29Pulmonary Embolism - prevention & control
30Relapse
31Risk Assessment
32Risk Factors
33Secondary Prevention
34Thrombosis
35Usage
36Venous Thrombosis - complications
37Venous Thrombosis - diagnosis
38Venous Thrombosis - epidemiology
39Venous Thrombosis - etiology
40Venous Thrombosis - prevention & control
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Kyrle, Paul Alexander, Dr
1Rosendaal, Frits R, Prof
2Eichinger, Sabine, MD
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9News PRO
10Pharma and Biotech Premium PRO
11Global News & ABI/Inform Professional
12ProQuest Central (Corporate)
13Bacteriology Abstracts (Microbiology B)
14Calcium & Calcified Tissue Abstracts
15Nursing & Allied Health Database
16Neurosciences Abstracts
17Toxicology Abstracts
18Virology and AIDS Abstracts
19Health & Medical Collection
20ProQuest Central (purchase pre-March 2016)
21Biology Database (Alumni Edition)
22Healthcare Administration Database (Alumni)
23Medical Database (Alumni Edition)
24Psychology Database (Alumni)
25Science Database (Alumni Edition)
26STEM Database
27ProQuest Pharma Collection
28Public Health Database
29Lancet Titles
30ProQuest SciTech Collection
31ProQuest Natural Science Collection
32Hospital Premium Collection
33Hospital Premium Collection (Alumni Edition)
34ProQuest Central (Alumni) (purchase pre-March 2016)
35Research Library (Alumni Edition)
36ProQuest Central (Alumni Edition)
37British Nursing Database
38British Nursing Index
39ProQuest Central Essentials
40Biological Science Collection
41eLibrary
42ProQuest Central
43Natural Science Collection
44Environmental Sciences and Pollution Management
45ProQuest Central Korea
46British Nursing Index (BNI) (1985 to Present)
47Health Research Premium Collection
48Health Research Premium Collection (Alumni)
49ProQuest Central Student
50Research Library Prep
51AIDS and Cancer Research Abstracts
52SciTech Premium Collection
53British Nursing Index
54Consumer Health Database (Alumni Edition)
55ProQuest Health & Medical Complete (Alumni)
56Nursing & Allied Health Database (Alumni Edition)
57ProQuest Newsstand Professional
58ProQuest Biological Science Collection
59Consumer Health Database
60Health & Medical Collection (Alumni Edition)
61Healthcare Administration Database
62Medical Database
63Psychology Database
64Research Library
65Science Database
66Algology Mycology and Protozoology Abstracts (Microbiology C)
67Biological Science Database
68Research Library (Corporate)
69Nursing & Allied Health Premium
70ProQuest One Academic Eastern Edition
71ProQuest One Academic
72ProQuest One Academic UKI Edition
73ProQuest Central Basic
74SIRS Editorial
75MEDLINE - Academic
76Aqualine
77Risk Abstracts
78Safety Science and Risk
79Water Resources Abstracts
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Kyrle, Paul Alexander, Dr
1Rosendaal, Frits R, Prof
2Eichinger, Sabine, MD
formatjournal
genrearticle
ristypeJOUR
atitleRisk assessment for recurrent venous thrombosis
jtitleThe Lancet (British edition)
addtitleLancet
date2010
risdate2010
volume376
issue9757
spage2032
epage2039
pages2032-2039
issn0140-6736
eissn1474-547X
codenLANCAO
abstractSummary Venous thrombosis is a common disease that frequently recurs. Recurrence can be prevented by anticoagulants, albeit at the cost of bleeding. Thus, assessment of the risk of recurrence is important to balance the risks and benefits of anticoagulation treatment. Many clinical and laboratory risk factors for recurrent venous thrombosis have been established. Nevertheless, prediction of recurrence in an individual patient remains a challenge. Detection of some laboratory markers is associated with only a moderate risk of recurrence, and the relevance of others is not known. Many patients have several risk factors and the effect of combined defects is obscure. Routine screening for these laboratory markers should therefore be abandoned. Risk assessment can be improved by measurement of global markers that encompass the effects of clotting and fibrinolytic disorders. Analysis of preliminary data suggests that risk assessment can also be refined through integration of prothrombotic coagulation changes and clinical risk factors.
copKidlington
pubElsevier Ltd
pmid21131039
doi10.1016/S0140-6736(10)60962-2